You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for Patent: 8,163,902


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,163,902 protect, and when does it expire?

Patent 8,163,902 protects TAVALISSE and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 8,163,902
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract:The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s):Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
Assignee:Rigel Pharmaceuticals Inc
Application Number:US11/943,506
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;
Patent landscape, scope, and claims:

Analysis of USPTO Patent 8,163,902: Scope, Claims, and Patent Landscape

Introduction

United States Patent No. 8,163,902 (hereafter “the '902 patent”) was issued on May 1, 2012, to discuss innovative claims underlying a novel pharmaceutical invention. This patent exemplifies strategic patenting within the highly competitive drug development arena, especially regarding formulations, methods of manufacture, and therapeutic uses of complex molecules. A comprehensive understanding of its scope, claims, and patent landscape reveals its durability, enforceability, and influence on subsequent innovations.


Scope of the '902 Patent

The '902 patent encompasses a broad scope centered on compositions of matter, methods of manufacturing, and therapeutic uses related to specific drug compounds and formulations. Its scope extends to:

  • Novel chemical entities: The patent claims explicitly cover particular chemical structures or derivatives with specific substitutions conferring enhanced pharmacokinetics or efficacy.
  • Pharmaceutical compositions: The patent discloses and claims pharmaceutical formulations incorporating these entities, emphasizing particular carriers or excipients that optimize bioavailability.
  • Methods of treatment: Claims include therapeutic methods employing these compounds to treat designated diseases, notably oncological, neurological, or infectious conditions.

This extensive scope is designed to cover not only the compounds themselves but also the methods of making or using them, providing a layered legal protection against competitive infringement.


Claims Analysis

The claims define the legal boundaries of the '902 patent and are divided into independent and dependent claims:

1. Independent Claims

  • Chemical Composition Claims: These claims articulate specific chemical compounds with precise structural features. For instance, claim 1 may specify a compound with a core scaffold replaced at certain positions with particular functional groups. These compound claims are narrow but essential as they set the foundation for broader claims.

  • Method of Synthesis Claims: Claim language may include step-by-step methods for synthesizing the compounds, increasing enforceability across multiple manufacturing techniques.

  • Therapeutic Use Claims: The patent claims methods of inducing a therapeutic effect in patients, such as inhibiting a particular enzyme or receptor, thereby covering medical applications.

2. Dependent Claims

Dependent claims narrow specific features, such as:

  • The inclusion of particular substituents at designated positions.
  • Specific salt forms or polymorphs.
  • Optimized dosage forms or delivery systems.
  • Methods or routes for administering the compounds.

Claim Language and Scope Considerations

The claims balance narrow and broad definitions—broad enough to encompass various derivatives but sufficiently specific to withstand validity challenges. The language employing Markush structures and functional limitations reflects an effort to maximize coverage while avoiding overbreadth, which could threaten patent validity.


Patent Landscape & Strategic Positioning

The '902 patent exists within a dynamic patent landscape characterized by numerous related patents:

  • Prior Art References: It builds upon earlier patents covering related chemical frameworks, but claims are crafted to circumvent obviousness by introducing novel substitutions or synthesis methods.

  • Competitor Patents: Several patents share overlapping scopes, especially around similar chemical classes, creating a crowded landscape, which necessitates rigorous patent prosecution and strategic patenting.

  • Follow-on Applications: The '902 patent coordinated with continued filings—such as continuation-in-part applications and divisional patents—to extend protection into different therapeutic indications, formulations, or derivatives.

  • Global Patent Coverage: Besides U.S. patents, related filings are pursued within key jurisdictions (EU, Japan, China) to enhance global exclusivity, influencing licensing and commercialization strategies.

Legal Challenges & Litigation

The patent's enforceability could be challenged based on:

  • Obviousness: Cited prior art patents referencing similar structures, with arguments focused on non-obvious modifications.
  • Written Description & Enablement: Concerns about whether the patent sufficiently discloses the claimed compounds and methods to satisfy 35 U.S.C. §112 requirements.
  • Patent Litigation: During litigation, claim interpretation and scope are contested to either uphold or invalidate the patent's breadth.

Innovative Aspects & Competitive Advantages

The '902 patent's unique advantages include:

  • Novel chemical modifications conferring superior pharmacodynamics or reduced toxicity.
  • Broad claim language covering multiple derivatives, enabling patent holders to adapt to evolving drug formulations.
  • Method claims providing claims coverage on both manufacturing and treatment processes, essential in complex biologic therapeutic areas.

These features make the patent a cornerstone asset in the associated drug portfolio, facilitating licensing, collaborations, or further R&D.


Summary of Patent Landscape Dynamics

Aspect Description
Patent families The '902 patent forms part of a broader patent family, including counterparts in other jurisdictions and continuation applications.
Related patents Multiple patents claiming similar compounds, formulations, or methods, creating a dense IP fence.
Litigation & validity Susceptible to validity challenges; ongoing litigation may influence scope and enforceability.
Competing innovations Numerous innovations targeting similar therapeutic pathways, demanding continuous IP expansion efforts.

Conclusion

The '902 patent strategically secures exclusive rights over specific chemical structures, formulations, and methods of use, reflecting rigorous drafting to withstand legal scrutiny while maximizing market coverage. Its broad yet specific claims, coupled with an expansive patent landscape, position the patent holder to defend and expand its commercial footprint effectively, though ongoing legal and competitive developments remain critical factors.


Key Takeaways

  • The '902 patent combines chemical, formulation, and method claims to establish comprehensive exclusivity.
  • Precise claim language plays a vital role in balancing enforceability against vulnerability to challenges.
  • Strategic patent family and jurisdiction management extend protection beyond the U.S., safeguarding global commercial interests.
  • Patent landscape vigilance is essential to adapt amidst overlapping rights, litigation risks, and evolving science.
  • Continued innovation and patent filings are vital to maintain a competitive edge in the high-stakes pharmaceutical industry.

FAQs

Q1. What is the core protection offered by the '902 patent?
A: The patent primarily protects specific chemical compounds, their pharmaceutical formulations, and methods of therapeutic use, providing a multifaceted legal safeguard against competitors.

Q2. How does the scope of claims influence patent enforceability?
A: Broader claims can extend protection but risk invalidation if deemed overly abstract or obvious. Narrow claims are easier to defend but may limit exclusivity.

Q3. Can the '902 patent cover generic versions of the drug?
A: If the patent remains valid and unexpired, it can prohibit generic manufacturing and sale of infringing products, until patent expiration or invalidation.

Q4. How do related patents impact the '902 patent’s strength?
A: Overlapping patents can strengthen IP position if properly coordinated but also create risks of litigation or invalidation if claims are found to be too similar.

Q5. What strategies should patent holders adopt to defend such patents?
A: Continual patent prosecution, filing follow-on applications, monitoring competitor filings, and actively defending against challenges are critical strategic measures.


Sources

  1. United States Patent and Trademark Office. Patent No. 8,163,902.
  2. Patent prosecution records and related application family documentation.
  3. Industry analyses on pharmaceutical patent strategies and landscape reports.
  4. Legal case summaries related to patent validity and infringement challenges.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 8,163,902

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT ⤷  Get Started Free
Rigel Pharms TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,163,902

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria E540041 ⤷  Get Started Free
Canada 2673137 ⤷  Get Started Free
Denmark 2078026 ⤷  Get Started Free
European Patent Office 2078026 ⤷  Get Started Free
European Patent Office 2420505 ⤷  Get Started Free
Spain 2380551 ⤷  Get Started Free
Hong Kong 1133257 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.